FIELD: pharmaceutics, clinical medicine, chemico-pharmaceutical industry.
SUBSTANCE: the suggested method deals with preparing polyvinyl pyrrolidone solution followed by its purification, dissolving all components, sterilization of ready-to-use product and bottling. Moreover, one should pre-dissolve polyvinyl pyrrolidone in water at 20-35 C and laminar mixing for 20-30 min, then obtained solution should be supplemented with mineral salts and nonpyrogenic activated coal to keep the obtained solution with coal at pH being 5.6-6.0 and at 100-102 C at laminar mixing for 25-30 min, then solution should be cooled up to 20-30 C, then comes filtration of solution to remove coal at a filter with coal alluvium to perform, finally, pH correction up to 6.1-6.5. The innovation provides improved PVP properties due to purifying it against admixtures, obtains practically colorless and stable PVP preparation both at manufacturing moment and during storage period.
EFFECT: higher efficiency.
2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PURIFICATION OF SOLUTIONS OF POLYVINYLPYRROLIDONE | 1992 |
|
RU2057144C1 |
ANTIVIRAL AGENT IN LIQUID FORM AND METHOD FOR ITS PREPARATION | 2021 |
|
RU2768656C1 |
PREPARATION BASED UPON HUMAN RECOMBINANT ALPHA-2-INTERFERON FOR INJECTIONS IN DRY LYOPHILIZED FORM | 2002 |
|
RU2236866C2 |
METHOD OF BLOOD PLASMA SUBSTITUENT PREPARING | 1998 |
|
RU2136293C1 |
ARTIFICIAL SYNOVIA | 1986 |
|
RU2033162C1 |
GENETIC-ENGINEERING GAMMA-INTERFERON PREPARATION | 1994 |
|
RU2077336C1 |
MEDICINAL AGENT WITH VOLEMIC EFFECT AND METHOD FOR ITS PREPARING | 2003 |
|
RU2245714C1 |
METHOD FOR PRODUCTION OF APYROGENIC IMMUNOMODULATING AGENT | 2006 |
|
RU2309759C1 |
DEVICE FOR MANUFACTURE OF MEDICINAL POLYMERIC FORMS | 1994 |
|
RU2110249C1 |
MONOMETHYL AURISTATIN E CONJUGATE FOR PREPARING A COMPOSITION FOR TREATING PROSTATE CANCER | 2019 |
|
RU2729192C1 |
Authors
Dates
2004-11-27—Published
2003-09-25—Filed